Poison Control Center
Cairo, Egypt
NCT Number: NCT06478667
To evaluate the potential role of levosimendan as an inotropic agent in aluminum phosphide-induced cardiotoxicity
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Phase 3
Cairo, Egypt
Aluminum phosphide (ALP) is a well-known fumigant known also as rice pill or wheat pill. It is considered an ideal pesticide since it is effective to preserve stored grains against insects and rodents without leaving residues, in addition to its availability and low cost. In Egypt, it has become a common method of suicide over the last few years because it is cheap and easily accessible. Cardiomyocytes are one of the main targets for ALP. ALP-induced cardiotoxicity involves detrimental effects such as direct myocardial tissue damage, hypoperfusion, myocarditis, pericarditis, and arrhythmias leading to circulatory failure. Levosimendan, an inotropic agent, enhances cardiac contractility through calcium sensitization with minimal oxygen demand and, in turn, decreases the risk of arrhythmia. However, limited studies have investigated the role of levosimendan in the treatment of ALP induced cardiotoxicity.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Patients with acute ALP intoxication admitted to ICU of PCC-ASUH and developed cardiotoxicity with Poisoning Severity Score (PSS) 2 (moderate) or 3 (severe) that led to cardiogenic shock and necessitated administration of vasoactive medications
Exclusion criteria
inotropic agent
Time frame: acute phase of myocarditis in 24 hours
Maintain systolic blood pressure with adequate organ perfusion
Ain Shams University
Other
The Role of Levosimendan as Inotropic Agent in Acute Aluminum Phosphide-induced Cardiotoxicity: A Randomized Controlled Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05180240
Acute Myocarditis
Washington D.C., District of Columbia, United States
View Trial DetailsNCT04206163
Acute Myocarditis, Cardiac Sarcoidosis
Gothenburg, Sweden
View Trial DetailsNCT03018834
Acute Myocarditis
Paris, France
View Trial DetailsNCT04375748
Acute Myocarditis, COVID-19
Aix-en-Provence, France
View Trial Details